Captisol®

Search documents
Ligand to Participate in September Investor Conferences
GlobeNewswire News Room· 2025-08-19 20:00
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 a ...
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire· 2025-07-24 11:00
Group 1 - Ligand Pharmaceuticals will report its second quarter 2025 financial results on August 7, 2025, and will hold a conference call at 8:30 AM ET to discuss the results and provide a business update [1][2] - The company operates a business model focused on generating value for stockholders through a diversified portfolio of biotech and pharmaceutical product revenue streams, supported by a low corporate cost structure [3] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization to generate revenue [3] Group 2 - Ligand's Captisol® platform technology optimizes the solubility and stability of drugs, while the NITRICIL™ platform technology allows for tunable dosing and adjustable drug release profiles [3] - The company has established multiple alliances and licenses with major pharmaceutical companies, including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3]
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
Globenewswire· 2025-07-10 12:00
Core Insights - Ligand Pharmaceuticals' partner Pelthos Therapeutics has launched ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum, leading to a $5 million milestone payment for Ligand [1][2] Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [4] - The company aims to create a diversified portfolio of biotech and pharmaceutical revenue streams while maintaining a low corporate cost structure [4] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [4] Product Details - ZELSUVMI™ (berdazimer) is a nitric oxide-releasing topical gel indicated for treating molluscum contagiosum in patients aged one year and older [3] - It is the first and only approved topical prescription medication that can be applied at home, outside of a medical setting [3] - The product was developed using Ligand's proprietary NITRICIL™ technology platform [3] Financial Aspects - Following the merger between Pelthos Therapeutics and Channel Therapeutics, Ligand now owns 56% of Pelthos [2] - Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI and can earn up to an additional $5 million in commercial sales milestones [2]
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
GlobeNewswire News Room· 2025-07-02 11:00
Core Insights - Pelthos Therapeutics Inc. is set to launch ZELSUVMI™ for treating Molluscum contagiosum infections in July 2025, following the completion of a merger with Channel Therapeutics Corporation [1][2] - Ligand Pharmaceuticals has invested $18 million in Pelthos and will receive a 13% royalty on worldwide sales of ZELSUVMI [1][2] - Pelthos will begin trading on the NYSE American exchange under the ticker symbol "PTHS" on July 2, 2025 [1] Company Developments - The merger between Ligand's subsidiary LNHC, Inc. and Channel Merger Sub Inc. has been completed, forming Pelthos Therapeutics Inc. [1][2] - Pelthos raised $50.1 million in equity capital, with $32 million from a group of strategic investors and $18 million from Ligand [2] - The capital raised will support the commercial launch of ZELSUVMI and includes the cancellation of approximately $18.8 million in bridge capital previously advanced to Pelthos [2] Product Information - ZELSUVMI (berdazimer) is a topical gel approved for treating Molluscum contagiosum, a common skin infection affecting an estimated 16.7 million people in the U.S. [3] - It is the first and only prescription medication for this condition that can be administered at home by patients or caregivers [3] - Pelthos is also evaluating the development of Channel's existing NaV 1.7 programs for various types of chronic pain and post-surgical nerve blocks [3]
Ligand Announces 2025 Investor Day in New York City
Globenewswire· 2025-06-11 11:00
Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [3] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [3] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [3] Upcoming Investor Day - Ligand Pharmaceuticals will host an Investor Day in New York City on December 9, 2025, at 10 a.m. Eastern Time [1] - The event will feature presentations from Ligand's senior management team discussing the company's strategy, investment activity, royalty portfolio, and long-term financial outlook [2] - A live webcast of the event will be available on Ligand's Investor Relations website, with a detailed agenda and dial-in information to be provided closer to the event [2] Technology Platforms - Ligand operates two infrastructure-light royalty-generating technology platforms: Captisol® and NITRICIL™ [3] - The Captisol® platform is designed to optimize the solubility and stability of drugs through a chemically modified cyclodextrin structure [3] - The NITRICIL™ platform allows for tunable dosing and adjustable drug release profiles, targeting a broad range of indications [3] Partnerships and Alliances - Ligand has established multiple alliances and licenses with major pharmaceutical companies, including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3]
Ligand Reports First Quarter 2025 Financial Results
Globenewswire· 2025-05-08 11:00
Core Insights - Ligand Pharmaceuticals reported a strong first quarter performance with total revenues of $45.3 million, a 46% increase from $31.0 million in the same period of 2024, driven by a 44% growth in royalty revenue [4][5] - The company reaffirmed its 2025 financial guidance, expecting total revenues between $180 million and $200 million, with adjusted earnings per diluted share projected to be between $6.00 and $6.25 [8][7] - Ligand's CEO highlighted the strength of the commercial royalty portfolio and the strategic transaction with Channel Therapeutics to accelerate the launch of ZELSUVMI, which is expected to create significant value for shareholders [3][9] Financial Performance - Total revenues for Q1 2025 were $45.3 million, with royalties contributing $27.5 million and Captisol sales at $13.5 million [4][5] - Research and development expenses surged to $50.1 million, primarily due to a one-time charge of $44.3 million related to a royalty financing agreement with Castle Creek Biosciences [4][5] - The GAAP net loss for Q1 2025 was $42.5 million, or $2.21 per share, compared to a net income of $86.1 million, or $4.75 per diluted share, in Q1 2024 [5][29] Strategic Transactions - Ligand announced a merger agreement with Channel Therapeutics, which will be supported by $50 million in capital from strategic investors [9][10] - The combined entity will focus on the commercialization of ZELSUVMI, the first FDA-approved prescription therapy for molluscum contagiosum infections [11][9] - Ligand's investment of $18 million in the combined company reflects its commitment to the growth of Pelthos Therapeutics [10][9] Portfolio Updates - Verona reported Ohtuvayre net sales of $71.3 million for Q1 2025, a 95% increase compared to the previous quarter [13] - Travere Therapeutics received European Commission approval for Filspari, enhancing its market position [14] - UroGen and Merck also reported significant advancements in their respective product pipelines, indicating a robust biopharmaceutical landscape [15][17] Cash Position - As of March 31, 2025, Ligand had cash, cash equivalents, and short-term investments totaling $208.9 million, including $24.2 million in Viking Therapeutics common stock [6][32]
Ligand to Participate in May Investor Conferences
Globenewswire· 2025-05-01 11:00
Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [2] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [2] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [2] Upcoming Investor Conferences - Ligand management will participate in the H.C. Wainwright Royalty Company Conference on May 13, 2025, at 3:30 p.m. ET, including a fireside chat and one-on-one meetings [4] - Management will also take part in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, at 2:05 p.m. ET, featuring a fireside chat and one-on-one meetings [4] - Additionally, Ligand will engage in one-on-one meetings at the Craig-Hallum Institutional Investor Conference on May 28, 2025 [4] Technology Platforms - Ligand operates two infrastructure-light royalty-generating technology platforms: Captisol® and NITRICIL™ [2] - The Captisol® platform is designed to optimize the solubility and stability of drugs through a chemically modified cyclodextrin structure [2] - The NITRICIL™ platform allows for tunable dosing, enabling adjustable drug release profiles for proprietary formulations targeting a broad range of indications [2] Investor Relations - The company utilizes its investor relations website and social media to disclose material non-public information and comply with disclosure obligations under Regulation FD [3] - Investors are encouraged to monitor the company's website and social media accounts for updates, press releases, SEC filings, and public conference calls [3]